Paul Hudson, Sanofi CEO (Eric Piermont/AFP viaGetty Images)

Sanofi CEO Paul Hud­son dives deep­er in­to mR­NA, buy­ing out an un­der-the-radar Fred Hutch spin­out

Sanofi CEO Paul Hud­son may not be ful­ly on board with the mR­NA rev­o­lu­tion, but he ev­i­dent­ly still be­lieves in the tech­nol­o­gy’s po­ten­tial.

On Fri­day af­ter­noon, Sanofi an­nounced that they bought out the lit­tle-known mR­NA biotech Tidal Ther­a­peu­tics, hop­ing to lever­age their tech­nol­o­gy to treat can­cer and im­muno­log­i­cal dis­or­ders. Spun out of the Fred Hutch in­sti­tute in 2019 and seed­ed at Cam­bridge’s Lab­Cen­tral, the young com­pa­ny will now re­ceive $160 mil­lion in cash and $310 mil­lion in po­ten­tial mile­stones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.